CRSP240913P46000
- 1.35
- -0.10-6.90%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Express News | CRISPR Therapeutics AG : Truist Securities Cuts Target Price to $100 From $120
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Express News | Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
Crispr Therapeutics Is Maintained at Hold by Stifel
Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler
Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital
Express News | Needham Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
CRISPR Therapeutics Analyst Ratings
Barclays Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating